HK1167395A1 - C-aryl glucoside derivatives, preparation process and pharmaceutical use thereof c- - Google Patents
C-aryl glucoside derivatives, preparation process and pharmaceutical use thereof c-Info
- Publication number
- HK1167395A1 HK1167395A1 HK12108091.7A HK12108091A HK1167395A1 HK 1167395 A1 HK1167395 A1 HK 1167395A1 HK 12108091 A HK12108091 A HK 12108091A HK 1167395 A1 HK1167395 A1 HK 1167395A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- preparation process
- pharmaceutical use
- glucoside derivatives
- aryl glucoside
- aryl
- Prior art date
Links
- 229930182478 glucoside Natural products 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/18—Acyclic radicals, substituted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/04—Carbocyclic radicals
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010249618 | 2010-08-10 | ||
CN2010105896065A CN102372722A (zh) | 2010-08-10 | 2010-12-06 | C-芳基葡萄糖苷衍生物、其制备方法及其在医药上的应用 |
PCT/CN2011/076680 WO2012019496A1 (zh) | 2010-08-10 | 2011-06-30 | C-芳基葡萄糖苷衍生物、其制备方法及其在医药上的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1167395A1 true HK1167395A1 (en) | 2012-11-30 |
Family
ID=45567352
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK12108091.7A HK1167395A1 (en) | 2010-08-10 | 2012-08-17 | C-aryl glucoside derivatives, preparation process and pharmaceutical use thereof c- |
Country Status (12)
Country | Link |
---|---|
US (1) | US8609622B2 (xx) |
EP (1) | EP2604612B1 (xx) |
JP (1) | JP5984808B2 (xx) |
KR (1) | KR101862891B1 (xx) |
CN (2) | CN102372722A (xx) |
BR (1) | BR112013002125A2 (xx) |
CA (1) | CA2807034C (xx) |
ES (1) | ES2581728T3 (xx) |
HK (1) | HK1167395A1 (xx) |
MX (1) | MX2013001098A (xx) |
RU (1) | RU2606501C2 (xx) |
WO (1) | WO2012019496A1 (xx) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014512399A (ja) * | 2011-04-25 | 2014-05-22 | ベイジン・プレリュード・ファーム・サイ・アンド・テック・カンパニー・リミテッド | ナトリウム依存性グルコース輸送タンパク質阻害剤並びにその調製方法及び使用 |
JP2014530186A (ja) | 2011-09-13 | 2014-11-17 | パナセア バイオテック リミテッド | 新規sglt阻害剤 |
CN102627535A (zh) * | 2012-03-31 | 2012-08-08 | 天津药物研究院 | 含1,1-二苯基环丙基结构的化合物的制备方法 |
CN103450214B (zh) * | 2012-05-29 | 2016-04-06 | 广东东阳光药业有限公司 | 吡喃葡萄糖基衍生物、其制备方法及其在医药上的应用 |
EP3466431B1 (en) | 2013-03-14 | 2023-11-15 | MSD International GmbH | Crystalline forms and methods for preparing sglt2 inhibitors |
CN104151306A (zh) * | 2013-05-13 | 2014-11-19 | 北京新天宇科技开发有限公司 | 一种坎格列净的新的制备方法 |
CN104619713B (zh) * | 2013-05-24 | 2017-06-16 | 四川海思科制药有限公司 | 氧杂双环衍生物、制备方法及其应用 |
WO2014206349A1 (zh) * | 2013-06-28 | 2014-12-31 | 四川海思科制药有限公司 | 氧杂-硫杂-双环[3.2.1]辛烷衍生物、制备方法及其用途 |
WO2015032272A1 (zh) * | 2013-09-09 | 2015-03-12 | 江苏豪森药业股份有限公司 | C-芳基葡糖苷衍生物、其制备方法及其在医药上的应用 |
WO2015043473A1 (en) * | 2013-09-25 | 2015-04-02 | Sunshine Lake Pharma Co., Ltd. | Glucopyranosyl derivatives and their uses in medicine |
ES2605886T3 (es) * | 2013-09-27 | 2017-03-16 | Sunshine Lake Pharma Co., Ltd. | Derivados de glucopiranosilo y sus usos en medicina |
US9884839B2 (en) * | 2014-01-03 | 2018-02-06 | Elexopharm Gmbh | Inhibitors of 17Beta-hydroxysteroid dehydrogenases type 1 and type 2 |
SG11201608936UA (en) | 2014-05-19 | 2016-12-29 | Pfizer | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of asgpr |
CN104031098A (zh) * | 2014-06-21 | 2014-09-10 | 李友香 | 降糖药物 |
CN104017031A (zh) * | 2014-06-21 | 2014-09-03 | 李友香 | 降血糖药物和组合物 |
CN105294785A (zh) * | 2014-07-02 | 2016-02-03 | 上海阳帆医药科技有限公司 | C-苯并五元杂芳环类芳基葡萄糖苷衍生物及其制备方法与用途 |
US20160002275A1 (en) * | 2014-07-03 | 2016-01-07 | Cadila Healthcare Limited | Process for preparation and purification of canagliflozin |
CN104119324B (zh) * | 2014-07-23 | 2016-03-30 | 齐鲁天和惠世制药有限公司 | 一种卡格列净的制备方法 |
CN105461762B (zh) * | 2014-09-27 | 2018-12-04 | 广东东阳光药业有限公司 | 吡喃葡萄糖基衍生物及其在医药上的应用 |
CN105992769B (zh) * | 2014-09-30 | 2019-04-02 | 江苏恒瑞医药股份有限公司 | 一种钠-葡萄糖协同转运蛋白2抑制剂的l-脯氨酸复合物、其一水合物及晶体 |
WO2016088081A1 (en) * | 2014-12-03 | 2016-06-09 | Sun Pharmaceutical Industries Limited | Processes for the preparation of ertugliflozin |
WO2016189463A1 (en) * | 2015-05-25 | 2016-12-01 | Sun Pharmaceutical Industries Limited | Ertugliflozin co-crystals and process for their preparation |
AU2017205545B2 (en) * | 2016-01-04 | 2019-11-21 | Je Il Pharmaceutical Co., Ltd. | C-glucoside derivative containing fused phenyl ring or pharmaceutically acceptable salt thereof, process for preparing same, and pharmaceutical composition comprising same |
CN106955273B (zh) * | 2016-01-11 | 2020-10-20 | 江苏恒瑞医药股份有限公司 | 一种含有钠-葡萄糖协同转运蛋白2抑制剂的药物组合物 |
CN107686496B (zh) * | 2016-08-05 | 2021-01-19 | 江苏恒瑞医药股份有限公司 | 一种钠-葡萄糖协同转运蛋白2抑制剂的制备方法 |
CN106674245B (zh) * | 2017-01-10 | 2019-07-26 | 北京中海康医药科技发展有限公司 | 吡喃葡萄糖基衍生物的制备及医药上的应用 |
CN109549939A (zh) * | 2017-09-26 | 2019-04-02 | 江苏恒瑞医药股份有限公司 | Sglt2抑制剂和dpp-4抑制剂联合在制备治疗糖尿病的药物中的用途 |
CN109806397A (zh) * | 2017-11-20 | 2019-05-28 | 江苏恒瑞医药股份有限公司 | Sglt2抑制剂与arb联合在制备治疗高血压等疾病的药物中的用途 |
WO2020039394A1 (en) | 2018-08-24 | 2020-02-27 | Novartis Ag | New drug combinations |
CN113330017B (zh) * | 2019-12-19 | 2023-01-31 | 上海研健新药研发有限公司 | 一种SGLTs抑制剂的纯化方法及其应用 |
CN113004349A (zh) * | 2019-12-19 | 2021-06-22 | 上海研健新药研发有限公司 | 一种SGLTs抑制剂的制备方法及其关键中间体 |
WO2021176096A1 (en) | 2020-03-05 | 2021-09-10 | Krka, D.D., Novo Mesto | Pharmaceutical composition comprising sglt2 inhibitor |
WO2021245253A1 (en) | 2020-06-05 | 2021-12-09 | Krka, D.D., Novo Mesto | Preparation of highly pure amorphous dapagliflozin |
CN114195748B (zh) * | 2020-09-17 | 2023-11-14 | 上海森辉医药有限公司 | 一种钠-葡萄糖协同转运蛋白2抑制剂的制备方法 |
CN112375087A (zh) * | 2020-11-27 | 2021-02-19 | 浙江天宇药业股份有限公司 | 一种脯氨酸恒格列净的合成方法 |
CN113880701A (zh) * | 2021-10-10 | 2022-01-04 | 浙江司太立制药股份有限公司 | 一种抗糖尿病药物中间体及其制备方法 |
CN116785268A (zh) * | 2022-03-14 | 2023-09-22 | 江苏万邦生化医药集团有限责任公司 | 一种sglt-2抑制剂的药物组合物 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1020944C (zh) | 1990-01-30 | 1993-05-26 | 阿图尔-费希尔股份公司费希尔厂 | 紧固件 |
CA2444481A1 (en) * | 2001-04-11 | 2002-10-24 | Bristol-Myers Squibb Company | Amino acid complexes of c-aryl glucosides for treatment of diabetes and method |
TWI254635B (en) | 2002-08-05 | 2006-05-11 | Yamanouchi Pharma Co Ltd | Azulene derivative and salt thereof |
US7202350B2 (en) * | 2003-03-14 | 2007-04-10 | Astellas Pharma Inc. | C-glycoside derivatives and salts thereof |
AR045173A1 (es) | 2003-08-01 | 2005-10-19 | Tanabe Seiyaku Co | Compuestos que poseen actividad inhibitoria contra transportador de glucosa dependiente de sodio |
US7858587B2 (en) * | 2006-09-21 | 2010-12-28 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted difluorobenzyl-benzene derivates, medicaments containing such compounds, their use and process for their manufacture |
PL2187742T3 (pl) | 2007-08-23 | 2018-06-29 | Theracos Sub, Llc | Pochodne (2s,3r,4r,5s,6r)-2-(4-chloro-3-benzylofenylo)-6-(hydroksymetylo) tetrahydro-2h-pirano-3,4,5-triolu do stosowania w leczeniu cukrzycy |
TWI523652B (zh) * | 2008-07-15 | 2016-03-01 | 泰瑞克公司 | 氘化苄基苯衍生物及使用方法 |
AR073118A1 (es) | 2008-08-22 | 2010-10-13 | Theracos Inc | Procesos para la preparacion de inhibidores de sglt2 y formas cristalinas del mismo. |
BRPI0918841B8 (pt) * | 2008-08-28 | 2021-05-25 | Pfizer | derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol, seus cristais, composições farmacêuticas e usos |
US20100167988A1 (en) | 2008-10-22 | 2010-07-01 | Auspex Pharmaceuticals, Inc. | Ethoxyphenylmethyl inhibitors of sglt2 |
WO2010074219A1 (ja) * | 2008-12-26 | 2010-07-01 | アステラス製薬株式会社 | ベンゾチオフェン化合物 |
SI2496583T1 (sl) * | 2009-11-02 | 2015-02-27 | Pfizer Inc. | Derivati dioksa-biciklo(3.2.1)oktan-2,3,4-triola |
JP2014517032A (ja) * | 2011-06-13 | 2014-07-17 | パナセア バイオテック リミテッド | 新規のsglt阻害剤 |
-
2010
- 2010-12-06 CN CN2010105896065A patent/CN102372722A/zh active Pending
-
2011
- 2011-06-30 RU RU2013107748A patent/RU2606501C2/ru active
- 2011-06-30 BR BR112013002125A patent/BR112013002125A2/pt not_active Application Discontinuation
- 2011-06-30 KR KR1020137005058A patent/KR101862891B1/ko active IP Right Grant
- 2011-06-30 CA CA2807034A patent/CA2807034C/en active Active
- 2011-06-30 CN CN201180003767.4A patent/CN102482290B/zh active Active
- 2011-06-30 EP EP11816055.5A patent/EP2604612B1/en active Active
- 2011-06-30 JP JP2013523477A patent/JP5984808B2/ja active Active
- 2011-06-30 US US13/813,045 patent/US8609622B2/en active Active
- 2011-06-30 WO PCT/CN2011/076680 patent/WO2012019496A1/zh active Application Filing
- 2011-06-30 ES ES11816055.5T patent/ES2581728T3/es active Active
- 2011-06-30 MX MX2013001098A patent/MX2013001098A/es unknown
-
2012
- 2012-08-17 HK HK12108091.7A patent/HK1167395A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
JP5984808B2 (ja) | 2016-09-06 |
CN102482290B (zh) | 2014-01-15 |
JP2013533291A (ja) | 2013-08-22 |
EP2604612B1 (en) | 2016-04-20 |
ES2581728T3 (es) | 2016-09-07 |
MX2013001098A (es) | 2013-06-05 |
KR20130095741A (ko) | 2013-08-28 |
WO2012019496A1 (zh) | 2012-02-16 |
US8609622B2 (en) | 2013-12-17 |
RU2013107748A (ru) | 2014-09-20 |
CN102482290A (zh) | 2012-05-30 |
CA2807034C (en) | 2019-05-07 |
KR101862891B1 (ko) | 2018-05-30 |
US20130130997A1 (en) | 2013-05-23 |
EP2604612A1 (en) | 2013-06-19 |
CN102372722A (zh) | 2012-03-14 |
RU2606501C2 (ru) | 2017-01-10 |
EP2604612A4 (en) | 2013-07-24 |
CA2807034A1 (en) | 2012-02-16 |
BR112013002125A2 (pt) | 2016-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1167395A1 (en) | C-aryl glucoside derivatives, preparation process and pharmaceutical use thereof c- | |
HK1161878A1 (en) | Dihydropteridinone derivatives, preparation process and pharmaceutical use thereof | |
ZA201209632B (en) | Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof | |
IL214175A (en) | Derivatives of aminotetralin, their pharmaceutical compositions and their use | |
ZA201300685B (en) | Anticancer derivatives,preparation thereof and therapeutic use thereof | |
PT2655375E (pt) | Derivados de pirimidinona, sua preparação e sua utilização farmacêutica | |
PL2562172T3 (pl) | Pochodne sfelaktonu, ich kompozycje farmaceutyczne, sposoby wytwarzania i zastosowania | |
ZA201209739B (en) | Levocarrimycin,pharmaceutical compositions,preparation methods and uses thereof | |
IL219888A0 (en) | Pyridine-pyridinone derivatives, preparation and therapeutic use thereof | |
EP2763998A4 (en) | TRI-HETEROCYCLIC DERIVATIVES, MANUFACTURING METHOD AND USES THEREOF | |
IL232577A0 (en) | The history of morpholinylbenzotriazine, their preparation and pharmaceutical preparations containing them | |
EP2386553A4 (en) | BENZIMIDAZOLE-4-CARBOXAMIDE DERIVATIVES, METHODS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | |
EP2786982A4 (en) | AMINO-PROPYLENE-GLYCOL DERIVATIVES, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
IL230219A0 (en) | History of dihydropyrazole, their preparation and pharmaceutical preparations containing them | |
IL233238A0 (en) | Sulphonylaminopyrrolidinone derivatives, their preparation and therapeutic use | |
IL219872A (en) | Quinazoline derivatives, their uses, their preparation, and their medications | |
IL214704A0 (en) | Oxazole pyridine derivatives, their preparation and pharmaceutical composition containing them | |
HK1209127A1 (en) | Macrolide derivatives, preparation thereof and therapeutic use thereof | |
IL225823A0 (en) | History of quinazoline, their preparation and pharmaceutical preparations containing them | |
HK1164861A1 (en) | Substituted 3-benzofuranyl-indol-2-one-3-acetamidopiperazine derivatives, preparation thereof, and therapeutic use thereof | |
IL225378A0 (en) | History of phenylquinazoline, their preparation and pharmaceutical preparations containing them | |
EP2565180A4 (en) | ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE PRODUCTION METHOD AND PHARMACEUTICAL COMPOSITION THEREWITH | |
SI2421864T1 (sl) | 1-pirazolo(4,3-c)izokinolinski derivati, njihova priprava in njihova terapevtska uporaba | |
IL220859A0 (en) | Alkyl-heterocycle-carbamate derivatives, their preparation and therapeutic application | |
IL217351A (en) | Derivatives 2 - Amino - Phenyl - Alkanol, Preparation and Pharmaceutical Preparations Containing Them |